Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 May 30;18(1):108.
doi: 10.1186/s12931-017-0592-z.

Electronic applications for the CFQ-R scoring

Andreas Ronit  1 , Marco Gelpi  2 , Jonathan Argentiero  3 , Inger Mathiesen  3 , Susanne D Nielsen  2 , Tanja Pressler  3 , Alexandra L Quittner  4
Affiliations

Electronic applications for the CFQ-R scoring

Andreas Ronit et al. Respir Res. .

Abstract

Patient reported outcomes (PROs) have become widely accepted outcome measures in cystic fibrosis (CF) and other respiratory diseases. The Cystic Fibrosis-Questionnaire-Revised (CFQ-R) is the best validated and most widely used PRO for CF. Data collection can be time-intensive, and electronic platforms would greatly facilitate the feasibility, utility and accuracy of administration of the CFQ-R. Given that the CFQ-R is utilized in virtually all clinical trials worldwide and is increasingly integrated into clinical practice, we developed a software application that will help users to administer, score and save CFQ-R data for all versions. All codes are open access, which will enable other PRO users to design similar applications for other respiratory diseases, such as primary ciliary dyskinesia and non-CF bronchiectasis.

Keywords: Application; Cystic fibrosis; Patient reported outcomes; Software.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Cystic fibrosis questionnaire revised (CFQ-R) application output. Output from the CFQ-R application (teen/adult version) showing demographic data and trajectories for 12 domains. The application calculates the score derived from the CFQ-R, on a 0–100 scale with higher scores indicating better health status. Other output forms are also available
See this image and copyright information in PMC

References

    1. U.S. Food and Drug Administration . Guidance for industry patientreported outcome measures: Use in medical product development to support labeling claims. 2009. - PubMed
    1. Venkatesan P. New European guidance on patient-reported outcomes. Lancet Oncol. 2016;17:e226. doi: 10.1016/S1470-2045(16)30113-9. - DOI - PubMed
    1. Retsch-Bogart GZ, Quittner AL, Gibson RL, Oermann CM, McCoy KS, Montgomery AB, Cooper PJ. Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis. Chest. 2009;135:1223–32. doi: 10.1378/chest.08-1421. - DOI - PMC - PubMed
    1. Black N, Burke L, Forrest CB, Sieberer UH, Ahmed S, Valderas JM, Bartlett SJ, Alonso J. Patient-reported outcomes: pathways to better health, better services, and better societies. Qual Life Res. 2016;25:1103–12. doi: 10.1007/s11136-015-1168-3. - DOI - PubMed
    1. Snyder CF, Aaronson NK, Choucair AK, Elliott TE, Greenhalgh J, Halyard MY, Hess R, Miller DM, Reeve DM, Santana M. Implementing patient-reported outcomes assessment in clinical practice: a review of the options and considerations. Qual Life Res. 2012;21:1305–14. doi: 10.1007/s11136-011-0054-x. - DOI - PubMed

Publication types